---
schema_version: "secwatch.filing_event.v1"
accession: "0000896622-25-000026"
form_type: "8-K"
ticker: "ATR"
cik: "0000896622"
company_name: "APTARGROUP, INC."
filed_at: "2025-07-31T23:59:59+00:00"
generated_at: "2026-05-17T22:38:27.246411+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# AptarGroup Q2 2025: adj. EPS $1.66 (+18% YoY), sales $966M (+6%), adj. EBITDA margin 22.6%

## Summary
- Reported sales $966M (+6% YoY); core sales +3%; net income $112M (+24%); adj. EPS $1.66 vs $1.41.
- Pharma core +3% (Injectables +9%, Active Material Science +11%); adj. EBITDA margin 35.4% (+130 bps).
- Closures core +7% (food & bev); Beauty core +1% (personal care up, fragrance subdued).
- Q3 adj. EPS guidance $1.53-$1.61; includes ~$0.06-$0.07 legal fees for pharma IP litigation.
- Returned $100M to shareholders ($70M buybacks, $30M dividends); quarterly dividend $0.45 payable Aug 14.

## SEC filing metadata
- accession: 0000896622-25-000026
- form_type: 8-K
- ticker: ATR
- cik: 0000896622
- company_name: APTARGROUP, INC.
- filed_at: 2025-07-31T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/896622/000089662225000026/0000896622-25-000026-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/896622/000089662225000026/atr-20250731.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000896622-25-000026
- JSON: https://secwatch.observer/filing/0000896622-25-000026.json
- Plain text: https://secwatch.observer/filing/0000896622-25-000026.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.